Biora Therapeutics, Inc. (NASDAQ:BIOR – Get Free Report) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 140,800 shares, a decline of 93.4% from the September 30th total of 2,130,000 shares. Currently, 4.1% of the company’s shares are sold short. Based on an average daily volume of 30,500 shares, the short-interest ratio is presently 4.6 days.
Biora Therapeutics Trading Up 15.7 %
Shares of Biora Therapeutics stock traded up $0.55 during trading on Friday, reaching $4.05. The company’s stock had a trading volume of 125,692 shares, compared to its average volume of 34,589. The firm has a market cap of $14.90 million, a PE ratio of -0.07 and a beta of 1.22. Biora Therapeutics has a fifty-two week low of $3.38 and a fifty-two week high of $21.10. The company has a 50-day moving average price of $5.94 and a two-hundred day moving average price of $6.42.
Biora Therapeutics (NASDAQ:BIOR – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($3.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.50) by $1.00. The company had revenue of $0.32 million for the quarter. On average, analysts predict that Biora Therapeutics will post -12.45 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on BIOR
Biora Therapeutics Company Profile
Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.
Featured Articles
- Five stocks we like better than Biora Therapeutics
- How is Compound Interest Calculated?
- Texas Roadhouse Stock Steering for New Highs This Year
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Invest in the FAANG Stocks
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Biora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.